CJC-1295 + Ipamorelin Blend Dosage Protocol
Reconstitution and dosing guide for the CJC-1295 (No DAC) + Ipamorelin blend, a 10 mg growth-hormone-secretagogue stack, most commonly a 1 : 1 (5 mg + 5 mg) combination.
Quickstart Highlights
This is the classic growth-hormone-releasing stack. CJC-1295 (No DAC, i.e. Modified GRF 1-29) is a GHRH analog that increases the amount of growth hormone released per pulse, while Ipamorelin is a selective GHS-R1a agonist (a ghrelin mimetic) that triggers a clean GH pulse with minimal effect on cortisol or prolactin. Used together they act on two complementary pathways. The 10 mg vial is most commonly a 1 : 1 split (5 mg of each peptide).
- Composition: 10 mg total blend, commonly 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin
- Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL of each peptide
- Easy measuring: At 2.5 mg/mL each, 1 unit (0.01 mL) on a U-100 syringe ≈ 25 mcg CJC-1295 + 25 mcg Ipamorelin
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, protected from light, use within 2–4 weeks
Dosing & Reconstitution Guide
Subcutaneous protocol; the standard research dose is 100 mcg of each peptide per injection
Subcutaneous Protocol (10 mg vial, 2 mL = 2.5 mg/mL each)
| Protocol | Per-dose (each) | Frequency | Units (U-100) |
|---|---|---|---|
| Standard | 100 mcg CJC + 100 mcg Ipa | 1× daily, before bed | 4 units (0.04 mL) |
| Intensive | 100 mcg CJC + 100 mcg Ipa | 2–3× daily | 4 units (0.04 mL) per dose |
Administration: Inject on an empty stomach, avoid food, and especially carbohydrates, for 30–60 minutes around dosing, since elevated blood sugar/insulin blunts the GH pulse. Before bed is the most common timing. At one 100/100 mcg dose per day, a 10 mg vial provides roughly 50 doses.
Reconstitution Steps
- Allow the vial to reach room temperature (15–20 minutes out of cold storage).
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming.
- Gently swirl or roll until dissolved (do not shake).
- Label with date and concentration; refrigerate at 2–8 °C, protected from light.
Result: 2.5 mg/mL of each peptide (5 mg/mL total blend)
How This Works
CJC-1295 (No DAC) is a Modified GRF 1-29, a growth-hormone-releasing hormone (GHRH) analog. It binds GHRH receptors on the pituitary to amplify the size of each natural GH pulse, while its short action preserves the body’s normal pulsatile rhythm.
Ipamorelin is a selective growth-hormone secretagogue (GHS-R1a / ghrelin-receptor agonist) that initiates a GH pulse through a separate pathway, without the appetite, cortisol, or prolactin effects seen with less selective secretagogues. Pairing a GHRH analog with a GHS is studied for a larger, cleaner combined GH release than either alone.
Key Administration Notes
- Dose on an empty stomach; before bed best mimics natural nocturnal GH release.
- Rotate injection sites; use new sterile insulin syringes and a sharps container.
- Doses are per peptide; one injection volume delivers both simultaneously.
- Document dose, timing, and site for consistency.
References
Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog. View Source
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. View Source
⚠️ Research & Educational Purposes Only
This information is provided for research and educational purposes only. The peptides discussed are intended for laboratory research use only and are not approved for human consumption. Always consult qualified healthcare professionals for medical advice. Individual results may vary. This is not medical advice.